Summary
Unable to verify alignment because the provided labeling excerpts are for Dextrose Injection (50%) while the claims reference a different formulation (Dextrose 2.5% and sodium chloride 0.11%). Additionally, several claims contain physico-chemical assertions and clinical use statements that are not supported by the provided label excerpts.
Category Scores
Accurate Statements
It is administered intravenously.
Supported only in a general sense; however, the label excerpt provided explicitly says: 'Administer Dextrose Injection (50%) intravenously. Do not administer ... subcutaneously or intramuscularly.'
Potential risks of intravenous fluid therapy include fluid overload.
Supported for Dextrose Injection (50%) under Warnings/Precautions 5.4: 'can cause fluid overload including pulmonary edema.'
Potential localized reactions at the IV site include phlebitis or infiltration.
Supported for Dextrose Injection (50%) under 5.3/6: 'may cause phlebitis and thrombosis at the site of injection' and adverse reactions include 'extravasation, phlebitis, thrombosis.' (Infiltration is not explicitly stated as the term used, but site reactions are described.)
Unsupported Statements
Dextrose 2.5% and sodium chloride 0.11% in a plastic container is a sterile solution used for intravenous fluid administration.
Provided labeling excerpts are for Dextrose Injection (50%) and do not support sterility, plastic container, or that this specific 2.5% dextrose/0.11% sodium chloride combination is labeled or described.
The solution combines dextrose, which provides calories.
The label for Dextrose Injection (50%) states it 'provides a source of carbohydrate calories,' but the provided claim refers to a different concentration/combination (2.5% dextrose/0.11% sodium chloride). Not supported for that specific formulation.
The solution combines sodium chloride, which helps maintain fluid balance.
No label excerpt provided describes sodium chloride content or its specific physiologic claim for this product.
This intravenous solution serves as a source of hydration and calories.
The provided label excerpt supports calories for Dextrose Injection (50%), but does not support 'source of hydration' nor the specific 2.5%/0.11% combination.
It is administered to patients who cannot take sufficient fluids or nutrients by mouth.
The indication excerpt provided only supports insulin-induced hypoglycemia treatment for Dextrose Injection (50%); no such indication is provided in the excerpts.
It is administered to help correct electrolyte imbalances.
No label excerpt indicates correction of electrolyte imbalances as an indication; warnings discuss electrolyte issues as risks.
The dextrose component can help prevent hypoglycemia.
Label excerpt supports treatment of insulin-induced hypoglycemia, not prevention phrasing; prevention is not explicitly supported.
The dextrose component requires careful monitoring in patients with diabetes to avoid hyperglycemia.
Label excerpts mention hyperglycemia risk and monitoring, but do not specifically mention 'patients with diabetes' as a population requiring careful monitoring.
The sodium chloride contributes to maintaining extracellular fluid volume.
No provided label excerpt supports sodium chloride physiologic effects.
The sodium chloride contributes to maintaining osmotic pressure.
No provided label excerpt supports sodium chloride physiologic effects.
Dextrose 2.5% is a hypotonic solution.
No provided label excerpt supports tonicity classification for Dextrose 2.5%.
Dextrose 2.5% has a lower solute concentration than blood.
No provided label excerpt supports this comparison for Dextrose 2.5%.
Dextrose 2.5% is suitable for rehydration.
No indication in the provided label excerpts supports rehydration for this formulation.
Dextrose 2.5% provides a modest caloric source.
No provided label excerpt supports caloric magnitude for Dextrose 2.5%.
Dextrose 2.5% does not cause significant fluid shifts into or out of cells.
No provided label excerpt supports statements about fluid shifts for Dextrose 2.5%.
Higher concentrations of dextrose are used for more substantial caloric support.
No provided label excerpt discusses dosing by caloric support or compares concentrations for caloric purposes.
Higher concentrations of dextrose are used to treat specific metabolic conditions.
Provided indication excerpt is specific to insulin-induced hypoglycemia; it does not support broad claims about 'specific metabolic conditions' or concentration-based therapeutic selection.
It is typically administered through a peripheral IV catheter or a central venous line.
For Dextrose Injection (50%), the label says 'When possible, administer ... into a central vein or large peripheral vein' and pediatric 2-11 years avoid peripheral. The claim is not aligned to pediatric caution and is phrased as 'typically' without support.
The rate and volume of administration are determined by a healthcare professional based on the patient's specific medical condition, fluid and electrolyte needs, and overall clinical status.
The label excerpt for Dextrose Injection (50%) provides dosing range and maximum infusion rate and says 'appropriate dosage depends on the age, weight, clinical and metabolic conditions ... and concomitant therapy.' It does not specifically state 'fluid and electrolyte needs' as part of the determination.
Products like dextrose 2.5% and sodium chloride 0.11% are basic intravenous solutions.
No provided label excerpt supports this classification.
Dextrose and sodium chloride are well-established and not subject to patent protection for their general therapeutic use.
No provided prescribing information excerpt addresses patents.
Patents typically apply to novel drug formulations, delivery systems, or specific medical uses.
No provided label excerpt addresses patents.
There are no specific patent expiry dates for the fundamental composition of dextrose 2.5% and sodium chloride 0.11%.
No provided label excerpt addresses patents/expiry dates.
Numerous pharmaceutical companies manufacture sterile intravenous solutions containing dextrose and sodium chloride.
No provided label excerpt addresses manufacturers or market availability.
Major suppliers include Baxter Healthcare, Fresenius Kabi, and B. Braun Medical Inc.
No provided label excerpt supports supplier/manufacturer claims.
Contradictions
Low
AI Statement
Dextrose 2.5% is a hypotonic solution.
Label Reference
Provided label describes Dextrose Injection (50%) as hypertonic with osmolarity >900 mOsm/L (Warnings/Precautions 5.3). It does not support hypotonic classification for Dextrose 2.5%.
Important Omissions
If the claim is intended to represent Dextrose Injection (50%), key on-label contraindications and major warnings (e.g., contraindications such as intracranial/intraspinal hemorrhage, severe dehydration, alcohol withdrawal, hypersensitivity; and risks such as hyperglycemia, hyperosmolar hyperglycemic state, hypersensitivity, phlebitis/thrombosis, hyponatremia, aluminum toxicity in <2 years) are not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Most claims are unsupported because the label excerpt provided is for Dextrose Injection (50%) while the claims are for Dextrose 2.5% plus sodium chloride 0.11%. Several clinical-use statements (rehydration, electrolyte imbalance correction, inability to take by mouth) are not supported by the provided labeling, increasing risk of off-label or incorrect indication framing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims reference a different product formulation (Dextrose 2.5%/NaCl 0.11%) and include indications/physiologic assertions not supported by the provided FDA label excerpt for Dextrose Injection (50%).
Suggested Improvement
Evaluate and rewrite claims strictly for the specific labeled product concentration/composition (Dextrose Injection (50%)) and include only label-supported indications, preparation/administration instructions, contraindications, and warning-based monitoring statements.